Restoration of transforming growth factor-β type II receptor reduces tumorigenicity in the human adrenocortical carcinoma SW-13 cell line

Hormone and Metabolic Research

Volumn 38, Issue 3, 2006, Pages 159-166

  Yamamoto, Natsuko ^a   Imai, J ^b   Watanabe, M ^b   Hiroi, N ^a   Sugano, S ^b   Yoshino, G ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Adrenocortical carcinoma; Cell proliferation; TGF insensitivity; TGF type II receptor; Transforming growth factor (TGF )

Indexed keywords

MESSENGER RNA; RECOMBINANT CYTOKINE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2;

ADRENAL CORTEX CARCINOMA; ARTICLE; CARCINOGENICITY; CELL GROWTH; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; HUMAN; HUMAN CELL; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ADRENAL CORTEX NEOPLASMS; ANIMALS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL DIVISION; CELL LINE, TUMOR; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSPLANTATION, HETEROLOGOUS;

MUS MUSCULUS;

EID: 33646235208     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-925185     Document Type: Article

References (43)

1. Roberts AB, Sporn MB. Transforming growth factor β. Adv Cancer Res 1988; 51: 107-145
2. Moses HL, Yang EY, Pietenpol JA. TGF-β stimulation and inhibition of cell proliferation: new mechanistic insights. Cell 1990; 63: 245-247
3. Derynck R, Akhurst RJ, Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nature Genet 2001; 29: 117-129
4. Massagué J, Blain SW, Lo RS. TGFβ signaling in growth control, cancer, and heritable disorders. Cell 2000; 103: 295-309
5. Wrana JL, Attisano L, Carcamo J, Zentella A, Doody J, Laiho M, Wang XF, Massagué J. TGF-β signals through heteromeric protein kinase receptor complex. Cell 1992; 71: 1003-1014
6. Derynck R, Zhang Y, Feng XH. Smads: transcriptional activators of TGF-β responses. Cell 1998; 95: 737-740
7. Massegué J. How cells read TGF-β signals. Nature Rev Mol Cell Biol 2000; 1: 169-178
8. Shi Y, Massegué J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 2003; 113: 685-700
9. 1/S-phase growth arrest. Mol Cell Biol 1991; 11: 1185-1194
10. Laiho M, De Caprio JA, Ludlow JW, Livingston DM, Massagué J. Growth inhibition by TGF-β linked to suppression of retinoblastoma protein phosphorylation. Cell 1990; 62: 175-185
11. Vassilopoulou-Sellin R, Schultz PN. Adrenocortical carcinoma. Cancer 2001; 92: 1113-1121
12. Reincke M, Karl M, Travis WH, Mastorakos G, Allolio B, Linehan HM, Chrousos GP. p53 mutations in human adrenocortical neoplasm: immunohistochemical and molecular studies. J Clin Endocrinol Metab 1994; 78: 790-794
13. Weber MM, Fottner C, Wolf E. The role of the insulin-like growth factor system in adrenocortical tumorigenesis. Eur J Clin Invest 2000; 30 (Suppl. 3): 69-75
14. Feige JJ, Cochet C, Savona C, Shi DL, Keramidas M, Defaye G, Chambaz EM. Transforming growth factor β1: an autocrine regulator of adrenocortical steroidogenesis. Endocr Res 1991; 17: 267-279
15. Stankovic AK, Dion LD, Parker CR Jr. Effects of transforming growth factor-β on human fetal adrenal steroid production. Mol Cell Endocrinol 1994; 99: 145-151
16. Riopel L, Branchaud CL, Goodyer CG, Adkar V, Lefebvre Y. Growth-inhibitory effect of TGF-β on human fetal adrenal cells in primary monolayer culture. J Cell Physiol 1989; 140: 233-238
17. Parker CR Jr, Stankovic AK, Harlin C, Carden L. Adrenocorticotropin interferes with transforming growth factor-β-induced growth inhibition of neocortical cells from the human fetal adrenal gland. J Clin Endocrinol Metab 1992; 75: 1519-1521
18. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbauth J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B, Brattain M, Willson KV. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science 1995; 268: 1336-1338
19. Park K, Kim SJ, Bang YJ, Park JG, Kim NK, Roberts AB, Sporn MB. Genetic changes in the transforming growth factor β (TGF-β) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-β. Proc Natl Acad Sci U S A 1994; 91: 8772-8776
20. Yang HK, Kang SH, Kim YS, Won K, Bang YJ, Kim SJ. Truncation of the TGF-β type II receptor gene results in insensitivity to TGF-β in human gastric cancer cells. Oncogene 1999; 18: 2213-2219
21. Vincent F, Hagiwara K, Ke Y, Stoner GD, Demetrick DJ, Bennett WP. Mutation analysis of the transforming growth factor β type II receptor in sporadic human cancers of the pancreas, liver, and breast. Biochem Biophys Res Commun 1996; 223: 561-564
22. Furuta K, Misao S, Takahashi K, Tagaya T, Fukuzawa Y, Ishikawa T, Yoshioka K, Kakumu S. Gene mutation of transforming growth factor β1 type II receptor in hepatocellular carcinoma. Int J Cancer 1999; 81: 851-853
23. Tomita S, Deguchi S, Miyaguni T, Muto Y, Tamamoto T, Toda T. Analyses of microsatellite instability and the transforming growth factor-β receptor type II gene mutation in sporadic human breast cancer and their correlation with clinicopathological features. Breast Cancer Res Treat 1999; 53: 33-39
24. Matoba H, Sugano S, Yamaguchi N, Miyachi Y. Expression of transforming growth factor-β1 and transforming growth factor-β type-II receptor mRNA in papillary thyroid carcinoma. Horm Metab Res 1998; 30: 624-628
25. Takada T, Iida K, Awaji T, Itoh K, Takahashi R, Shibui A, Yoshida K, Sugano S, Tujimoto G. Selective production of transgenic mice using green fluorescent protein as a marker. Nat Biotechnol 1997; 15: 458-461
26. Matzuk MM, Finegold MJ, Mather JP, Krummen L, Lu H, Bradley A. Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice. Proc Natl Acad Sci U S A. 1994; 91: 8817-8821
27. Beuschlein F, Looyenga BD, Bleasdale SE, Mutch C, Bavers DL, Parlow AF, Nilson JH, Hammer GD. Activin induces x-zone apoptosis that inhibits luteinizing hormone-dependent adrenocortical tumor formation in inhibin-deficient mice. Mol Cell Biol 2003; 23: 3951-3964
28. Arnaldi G, Freddi S, Mancini T, Kola B, Mantero F. Transforming growth factor β1: implications in adrenocortical tumorigenesis. Endocr Res 2000; 26: 905-910
29. Boccuzzi A, Terzolo M, Cappia S, De Giuli P, De Risi C, Leonardo E, Bovio S, Borriero M, Paccotti P, Angeli A. Different immunohistochemical patterns of TGF-β1 expression in benign and malignant adrenocortical tumours. Clin Endocrinol (Oxf) 1999; 50: 801-808
30. Le Roy C, Maisnier-Patin K, Leduque P, Li JY, Saez JM, Langlois D. Overexpression of a dominant-negative type 11 TGFβ receptor tagged with green fluorescent protein inhibits the effects of TGFβ on cell growth and gene expression of mouse adrenal tumor cell line Y-1 and enhances cell tumorigenicity. Mol Cell Endocrinol 1999; 158: 87-98
31. Sun L, Wu G, Willson JK, Zborowska E, Yang J, Rajkarunanayake I, Wang J, Gentry LE, Wang XF, Brattain MG. Expression of transforming growth factor β type II receptor leads to reduced malignancy in human breast cancer MCF-7 Cells. J Biol Chem 1994; 269: 26449-26455
32. Chang J, Park K, Bang YJ, Kim WS, Kim D, Kim SJ. Expression of transforming growth factor β type II receptor reduces tumorigenicity in human gastric cancer cells. Cancer Res 1997; 57: 2856-2859
33. Turco A, Coppa A, Aloe S, Baccheschi G, Morrone S, Zupi G, Colletta G. Overexpression of transforming growth factor β-type II receptor reduces tumorigenicity and metastastic potential of K-ras-transformed thyroid cells. Int J Cancer 1999; 80: 85-91
34. Weiss LM, Medeiros LJ, Vickery AL Jr. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 1989; 13: 202-206
35. Sasano H, Suzuki T, Moriya T. Discrening malignancy in resected adrenocortical neoplasms. Endocr Pathol 2001; 12: 397-406
36. Wachenfeld C, Beuschlein F, Zwermann O, Mota P, Fassnacht M, Alloloi B, Reincke M. Discerning malignancy in adrenocortical tumors: are molecular makers useful? Eur J Endocrinol 2001; 145: 335-341
37. Miyajima A, Asano T, Seta K, Asano T, Kakoi N, Hayakawa M. Loss of expression of transforming growth factor-β receptor as a prognostic factor in patients with renal cell carcinoma. Urology 2003; 61: 1072-1077
38. Kim IY, Ahn HJ, Lang S, Oefelein MG, Oyasu R, Kozlowski JM, Lee C. Loss of expression of transforming growth factor-β receptor is associated with poor prognosis in prostate cancer patients. Clin Cancer Res 1998; 4: 1625-1630
39. Muñoz-Antonia T, Li X, Reiss M, Jackson R, Antonia S. A mutation in the transforming growth factor β type II receptor gene promoter associated with loss of gene expression. Cancer Res 1996; 56: 4831-4835
40. Hahm KB, Cho K, Lee C, Im YH, Chang J, Choi SG, Sorensen PH, Thiele CJ, Kim SJ. Repression of the gene encoding the TGF-β type II receptor is a major target of the EWS-FLI1 oncoprotein. Nat Genet 1999; 23: 222-227
41. Yamamoto N. Reduced expression of transforming growth factor β type II receptor mRNA in the human adrenocortical carcinoma cell line SW-13. J Med Soc Toho Univ 2002; 49: 336-346
42. Vassilopoulou-Sellin R, Guinee VF, Klein MJ, Taylor SH, Hess KR, Schultz PN, Samaan NA. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer 1993; 71: 3119-3123
43. Bukowski RM, Wolfe M, Levine HS, Crawford DE, Stephens RL, Gaynor E, Harker WG. Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study. J Clin Oncol 1993; 11: 161-165